ReviewTransactions of the Royal Society of Tropical Medicine and Hygiene2021
Gastrointestinal manifestations in COVID-19.
Review in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- The Prevalence of Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Bowel ischemia in COVID-19: A systematic review.International journal of clinical practice · 2021Pooled it
- Association of Diabetes Mellitus and COVID-19-Related Pancreatic and Biliary Inflammatory Diseases.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical features and inflammatory signatures of patients with persistent gastrointestinal long COVID two years after severe SARS-CoV-2 infection.Scientific reports · 2026Article
- Esophageal motility disorders after COVID-19 infection.Scientific reports · 2025Observational
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Clinical features, treatments and prognosis of COVID-19 (Omicron) and hemorrhagic colitis: a case series study.BMC gastroenterology · 2025Article
- Association Between COVID-19 Vaccination and Gastrointestinal Manifestations: A Cross-Sectional Study.Health science reports · 2025Article
- Article
- Novel anti-inflammatory properties of mannose oligosaccharides in the treatment of inflammatory bowel disease via LGALS3 modulation.NPJ biofilms and microbiomes · 2025Article
- COVID-19 and Upper Gastrointestinal Bleeding; Etiology, Risk Factors, and Outcomes: A Case-Control Study.Middle East journal of digestive diseases · 2025Article
- New-onset gastrointestinal disorders in COVID-19 patients 3.5 years post-infection in the inner-city population in the Bronx.Scientific reports · 2024Article
- Cardiac Damage in Patients Infected with Different SARS-CoV-2 Variants of Concern.Microorganisms · 2024Article
- Post-Acute Sequelae of Covid-19: A System-wise Approach on the Effects of Long-Covid-19.American journal of medicine open · 2024Review
- Article
- Article
- Mortality risk of patients with intestinal obstruction.BMC cancer · 2024Article
- Impaired Cardiorespiratory Fitness of Elite Athletes after Asymptomatic or Mild SARS-CoV-2 Infection.Medicina (Kaunas, Lithuania) · 2024Article
- Glycosylation Modulation Dictates Trafficking and Interaction of SARS-CoV-2 S1 Subunit and ACE2 in Intestinal Epithelial Caco-2 Cells.Biomolecules · 2024Article
- Gastrointestinal Manifestations and Their Association with Neurologic and Sleep Problems in Long COVID-19 Minority Patients: A Prospective Follow-Up Study.Digestive diseases and sciences · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), a respiratory viral infection, has affected more than 78 million individuals worldwide as of the end of December 2020. Previous studies reported that severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome-related coronavirus infections may affect the gastrointestinal (GI) system. In this review we outline the important GI manifestations of COVID-19 and discuss the possible underlying pathophysiological mechanisms and their diagnosis and management. GI manifestations are reported in 11.4-61.1% of individuals with COVID-19, with variable onset and severity. The majority of COVID-19-associated GI symptoms are mild and self-limiting and include anorexia, diarrhoea, nausea, vomiting and abdominal pain/discomfort. A minority of patients present with an acute abdomen with aetiologies such as acute pancreatitis, acute appendicitis, intestinal obstruction, bowel ischaemia, haemoperitoneum or abdominal compartment syndrome. Severe acute respiratory syndrome coronavirus 2 RNA has been found in biopsies from all parts of the alimentary canal. Involvement of the GI tract may be due to direct viral injury and/or an inflammatory immune response and may lead to malabsorption, an imbalance in intestinal secretions and gut mucosal integrity and activation of the enteric nervous system. Supportive and symptomatic care is the mainstay of therapy. However, a minority may require surgical or endoscopic treatment for acute abdomen and GI bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.